Active Ingredient History
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-stream, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Bacterial Infections (approved 1985)
Respiratory Tract Infections (approved 1985)
Antibiotic Prophylaxis (Phase 4)
Ascites (Phase 2/Phase 3)
Bacteremia (Phase 4)
Bacterial Infections (Phase 3)
Colitis, Ulcerative (Phase 2)
Community-Acquired Infections (Phase 3)
Corneal Diseases (Phase 1)
Cystic Fibrosis (Phase 4)
Drugs, Investigational (Phase 4)
Enterobacteriaceae Infections (Phase 3)
Esophageal Achalasia (Phase 2/Phase 3)
Febrile Neutropenia (Phase 4)
Feeding and Eating Disorders (Phase 4)
Fever (Phase 4)
Fibrosis (Phase 2/Phase 3)
Gram-Negative Bacterial Infections (Phase 2)
Hamartoma (Phase 4)
Healthcare-Associated Pneumonia (Phase 4)
Healthy Volunteers (Phase 1)
HIV Infections (Phase 1/Phase 2)
Infections ()
Intestinal Neoplasms (Phase 1)
Intraabdominal Infections (Phase 4)
Leukemia (Phase 4)
Lung Diseases (Phase 4)
Lymphoma (Phase 4)
Melioidosis (Phase 2)
Meningitis (Phase 2)
Neoplasms (Phase 2)
Pancreatitis (Phase 4)
Peritoneal Dialysis (Phase 4)
Peritonitis (Phase 2/Phase 3)
Pharmacokinetics (Phase 1)
Pneumonia (Phase 3)
Pneumonia, Ventilator-Associated (Phase 4)
Premature Birth (Phase 4)
Pseudomonas aeruginosa (Phase 4)
Pyelonephritis (Phase 4)
Respiratory Tract Infections (Phase 2)
Safety (Phase 1)
Skin Diseases, Bacterial (Phase 3)
Skin Diseases, Infectious (Phase 3)
Staphylococcal Skin Infections (Phase 3)
Stomach Diseases (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue